AstraZeneca halts Phase 3 lung cancer trial of volrustomig after negative results

AstraZeneca announced on Monday that it is ending the Phase 3 study of its lung-cancer drug volrustomig after the trial failed to meet its primary efficacy endpoints.

The company said the data did not demonstrate the expected benefit for patients, prompting the decision to discontinue the late-stage program.

This marks the latest setback in a series of challenges for AstraZeneca’s oncology pipeline, which has seen several candidates falter in recent months.

AstraZeneca indicated it will reallocate resources to other promising assets in its portfolio and continue to explore alternative approaches for lung cancer treatment.

Investors are likely to monitor the impact of the trial termination on the company’s near-term earnings outlook and its broader strategic direction.